Physician profile
David S Keith
NPI 1639517568
$726.13
in general payments reported to CMS, 2019-2025
15 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.85 · 2020: $64.71 · 2021: $83.92 · 2022: $44.81 · 2023: $176 · 2024: $155 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $492.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $168.81 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $105.69 | 2023 | |
| Abbvie INC. | $72.38 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $62.45 | 2019-2021 | |
| Lilly USA, LLC | $60.56 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $46.09 | 2020-2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $35.68 | 2020-2021 | |
| Abbott Laboratories | $28.57 | 2022 | |
| Medtronic, INC. | $25.78 | 2023 | Vanta Adaptivestim |
| Exact Sciences Corporation | $24.16 | 2025 | The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.73 | 2025 | Jardiance |
| Dexcom, INC. | $21.44 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $19.29 | 2024 | |
| Astellas Pharma US INC | $19.02 | 2025 | Veozah |
| Merck Sharp & Dohme LLC | $14.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Keith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.